Finally, the restoration of TRPM3 channel activity suggests an immune-modulating action of NTX by remodeling the TRPM3-dependent Ca2+ signals, which will in turn affect NK cell functions, and support the hypothesis that NTX may have potential for use as a treatment for ME/CFS. The gene discussed is TRPM3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.